Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Eri Sugiyama
Observed name:
E. Sugiyama
Institutions:
National Cancer Centre Japan,
National Cancer Center Hospital East,
National Cancer Center Exploratory Oncology Research & Clinical Trial Center
Observed institutions:
National Cancer Centre Japan,
National Cancer Center Hospital East,
National Cancer Center Exploratory Oncology Research & Clinical Trial Center,
National Cancer Center Research Institute,
Nagoya University
ORCID:
0000-0002-2962-2853
Observed ORCID:
0000-0002-2962-2853
OpenAlex ID:
A5064185203
Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments
2022
·
Shogo Kumagai
, Shohei Koyama
, et al.
·
Cancer Cell
·
1,008
The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies
2020
·
Shogo Kumagai
, Yosuke Togashi
, et al.
·
Nature Immunology
·
866
Blockade of EGFR improves responsiveness to PD-1 blockade in EGFR -mutated non–small cell lung cancer
2020
·
Eri Sugiyama
, Yosuke Togashi
, et al.
·
Science Immunology
·
308
Signaling through the Phosphatidylinositol 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Axis Is Responsible for Aerobic Glycolysis mediated by Glucose Transporter in Epidermal Growth Factor Receptor (EGFR)-mutated Lung Adenocarcinoma
2015
·
Hideki Makinoshima
, Masahiro Takita
, et al.
·
Journal of Biological Chemistry
·
205
PDF
Microbiota-driven antitumour immunity mediated by dendritic cell migration
2025
·
Nina Yi-Tzu Lin
, Shota Fukuoka
, et al.
·
Nature
·
90
The CLIP1–LTK fusion is an oncogenic driver in non‐small‐cell lung cancer
2021
·
Hiroki Izumi
, Shingo Matsumoto
, et al.
·
Nature
·
76
Large-Scale Clinico-Genomic Profile of Non-Small Cell Lung Cancer with KRAS G12C: Results from LC-SCRUM-Asia Study
2022
·
Yutaro Tamiya
, Shingo Matsumoto
, et al.
·
Lung Cancer
·
46
PDF
Impact of single nucleotide polymorphisms on severe hepatotoxicity induced by EGFR tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring EGFR mutations
2015
·
Eri Sugiyama
, Shigeki Umemura
, et al.
·
Lung Cancer
·
32
Clinicogenomic Features and Targetable Mutations in NSCLCs Harboring BRAF Non-V600E Mutations: A Multi-Institutional Genomic Screening Study (LC-SCRUM-Asia)
2023
·
Tetsuya Sakai
, Shingo Matsumoto
, et al.
·
Journal of Thoracic Oncology
·
27
PDF
Efficacy of immune checkpoint inhibitors plus platinum-based chemotherapy as 1st line treatment for patients with non-small cell lung cancer harboring HER2 mutations: Results from LC-SCRUM-Asia
2024
·
Yuki Kato
, Hibiki Udagawa
, et al.
·
Lung Cancer
·
24
PDF
Association of gut microbiome with immune status and clinical response in solid tumor patients who received on anti-PD-1 therapies.
2018
·
Shota Fukuoka
, Motooka Daisuke
, et al.
·
Journal of Clinical Oncology
·
17
Clinical Significance of a Prospective Large Genomic Screening for SCLC: The Genetic Classification and a Biomarker-Driven Phase 2 Trial of Gedatolisib
2024
·
Shigeki Umemura
, Hibiki Udagawa
, et al.
·
Journal of Thoracic Oncology
·
15
Successful treatment with afatinib after grade 3 hepatotoxicity induced by both gefitinib and erlotinib in EGFR mutation-positive non-small cell lung cancer
2016
·
Yoshitaka Zenke
, Shigeki Umemura
, et al.
·
Lung Cancer
·
15
Clinical outcomes in patients with non-small cell lung cancer harboring EGFR Exon20 in-frame insertions in the near-loop and far-loop: Results from LC-SCRUM-Asia
2024
·
Masanobu Okahisa
, Hibiki Udagawa
, et al.
·
Lung Cancer
·
13
PDF
Bevacizumab plus platinum-based chemotherapy in advanced non-squamous non-small-cell lung cancer: a randomized, open- label phase 2 study (CLEAR)
2021
·
Hibiki Udagawa
, Eri Sugiyama
, et al.
·
Translational Lung Cancer Research
·
8
PDF
Solid Predominant Histology and High Podoplanin Expression in Cancer-Associated Fibroblast Predict Primary Resistance to Osimertinib in EGFR-Mutated Lung Adenocarcinoma
2024
·
Yuji Uehara
, Hiroki Izumi
, et al.
·
JTO Clinical and Research Reports
·
5
PDF
Randomized phase II study comparing cisplatin + pemetrexed + bevacizumab with carboplatin + paclitaxel + bevacizumab in treatment-naïve advanced non-squamous non-small cell lung cancer (CLEAR study)
2018
·
R. Koyama
, H. Udagawa
, et al.
·
Annals of Oncology
·
4
Abstract 7198: Preclinical efficacy of the combination of MEK inhibitor plus KRAS G12D inhibitor for non-small cell lung cancer with KRAS G12D
2025
·
Yu Tanaka
, Mirai Tsukuda
, et al.
·
Cancer Research
·
3
Higher incidence of EGFR exon 19 deletion in younger (age 40 or younger) patients with adenocarcinoma of the lung.
2012
·
Eri Sugiyama
, Koichi Goto
, et al.
·
Journal of Clinical Oncology
·
3
A large validation study of AI-powered PD-L1 analyzer compared to pathologists’ assessment of PD-L1 expression in lung cancer.
2025
·
Yoshitaka Zenke
, Kiyotaka Yoh
, et al.
·
Journal of Clinical Oncology
·
2
Clinical, genomic, and pathological features and therapeutic outcomes of non-small cell lung cancer with MTAP-loss.
2025
·
Hibiki Udagawa
, Shingo Matsumoto
, et al.
·
Journal of Clinical Oncology
·
2
Efficacy and safety of upfront radiotherapy with immune checkpoint inhibitors for brain metastasis in non-small cell lung cancer
2025
·
Yu Tanaka
, Hiroki Izumi
, et al.
·
Cancer Treatment and Research Communications
·
2
NET osis in pulmonary pleomorphic carcinoma
2024
·
Hajime Oi
, Tetsuro Taki
, et al.
·
Cancer Science
·
2
P1.03-027 Randomized Phase 2 Study Comparing CBDCA+PTX+BEV and CDDP+PEM+BEV in Treatment-Naïve Advanced Non-Sq NSCLC (CLEAR Study)
2017
·
S. Atagi
, H. Udagawa
, et al.
·
Journal of Thoracic Oncology
·
2
Efficacy of EGFR tyrosine kinase inhibitors in patients with non–small cell lung cancer with EGFR exon 19 insertions: clinical-genomic, preclinical analysis through LC-SCRUM-Asia (multi-institutional genomic screening registry)
2025
·
Yuji Uehara
, Hiroki Izumi
, et al.
·
Lung Cancer
·
1
Show more works
View as search
Works count:
47
Citation count:
2,781
H-index:
13
I10-index:
14
Year
Topic
Type